These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 26232615)

  • 1. Arginine vasopressin receptor signaling and functional outcomes in heart failure.
    Wasilewski MA; Myers VD; Recchia FA; Feldman AM; Tilley DG
    Cell Signal; 2016 Mar; 28(3):224-233. PubMed ID: 26232615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac fibroblasts and cellular cross talk in heart failure.
    Blaxall BC; Baudino TA; Kirshenbaum LA
    J Cardiovasc Transl Res; 2012 Dec; 5(6):737-8. PubMed ID: 23135992
    [No Abstract]   [Full Text] [Related]  

  • 3. Science review: Vasopressin and the cardiovascular system part 1--receptor physiology.
    Holmes CL; Landry DW; Granton JT
    Crit Care; 2003 Dec; 7(6):427-34. PubMed ID: 14624682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors.
    Juul KV; Bichet DG; Nielsen S; Nørgaard JP
    Am J Physiol Renal Physiol; 2014 May; 306(9):F931-40. PubMed ID: 24598801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasopressin promotes cardiomyocyte hypertrophy via the vasopressin V1A receptor in neonatal mice.
    Hiroyama M; Wang S; Aoyagi T; Oikawa R; Sanbe A; Takeo S; Tanoue A
    Eur J Pharmacol; 2007 Mar; 559(2-3):89-97. PubMed ID: 17275806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasopressin: a new target for the treatment of heart failure.
    Lee CR; Watkins ML; Patterson JH; Gattis W; O'connor CM; Gheorghiade M; Adams KF
    Am Heart J; 2003 Jul; 146(1):9-18. PubMed ID: 12851603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AVP-induced increase in AQP2 and p-AQP2 is blunted in heart failure during cardiac remodeling and is associated with decreased AT1R abundance in rat kidney.
    Lütken SC; Frøkiær J; Nielsen S
    PLoS One; 2015; 10(2):e0116501. PubMed ID: 25658446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conivaptan: a selective vasopressin antagonist for the treatment of heart failure.
    Schwarz ER; Sanghi P
    Expert Rev Cardiovasc Ther; 2006 Jan; 4(1):17-23. PubMed ID: 16375624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased vasopressin 1A receptor expression in failing human hearts.
    Zhu W; Tilley DG; Myers VD; Tsai EJ; Feldman AM
    J Am Coll Cardiol; 2014 Feb; 63(4):375-6. PubMed ID: 24140674
    [No Abstract]   [Full Text] [Related]  

  • 10. Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function.
    Lother A; Berger S; Gilsbach R; Rösner S; Ecke A; Barreto F; Bauersachs J; Schütz G; Hein L
    Hypertension; 2011 Apr; 57(4):746-54. PubMed ID: 21321305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure.
    Morooka H; Iwanaga Y; Tamaki Y; Takase T; Akahoshi Y; Nakano Y; Fujiki H; Miyazaki S
    Circ Heart Fail; 2012 Jul; 5(4):484-92. PubMed ID: 22628529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innate immune signaling induces expression and shedding of the heparan sulfate proteoglycan syndecan-4 in cardiac fibroblasts and myocytes, affecting inflammation in the pressure-overloaded heart.
    Strand ME; Herum KM; Rana ZA; Skrbic B; Askevold ET; Dahl CP; Vistnes M; Hasic A; Kvaløy H; Sjaastad I; Carlson CR; Tønnessen T; Gullestad L; Christensen G; Lunde IG
    FEBS J; 2013 May; 280(10):2228-47. PubMed ID: 23374111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardioprotective function of cardiac macrophages.
    Fujiu K; Wang J; Nagai R
    Cardiovasc Res; 2014 May; 102(2):232-9. PubMed ID: 24675722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recent advances in vasopressin receptors and signal transduction system].
    Terada Y; Marumo F
    Nihon Rinsho; 1993 Oct; 51(10):2655-60. PubMed ID: 8254935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myocyte apoptosis in heart failure.
    van Empel VP; Bertrand AT; Hofstra L; Crijns HJ; Doevendans PA; De Windt LJ
    Cardiovasc Res; 2005 Jul; 67(1):21-9. PubMed ID: 15896727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Congestive heart failure in rats is associated with increased collecting duct vasopressin sensitivity and vasopressin type 2 receptor reexternalization.
    Brønd L; Müllertz KM; Torp M; Nielsen J; Graebe M; Hadrup N; Nielsen S; Christensen S; Jonassen TE
    Am J Physiol Renal Physiol; 2013 Dec; 305(11):F1547-54. PubMed ID: 24089411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a cardiovascular rationale for the use of combined vasopressin V1a/V2 receptor antagonists?
    Goldsmith SR
    Am J Med; 2006 Jul; 119(7 Suppl 1):S93-6. PubMed ID: 16843092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiol antioxidants regulate angiotensin II AT1 and arginine vasopressin V1 receptor functions differently in vascular smooth muscle cells.
    Ullian ME; Beck CN; Walker LP; Fitzgibbon WR; Morinelli TA
    Am J Hypertens; 2009 Feb; 22(2):221-7. PubMed ID: 19039312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Long-term Blockade of Vasopressin Receptor Types 1a and 2 on Cardiac and Renal Damage in a Rat Model of Hypertensive Heart Failure.
    Ikeda T; Iwanaga Y; Watanabe H; Morooka H; Akahoshi Y; Fujiki H; Miyazaki S
    J Cardiovasc Pharmacol; 2015 Nov; 66(5):487-96. PubMed ID: 26248278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasopressin V1a and V1b receptors: from molecules to physiological systems.
    Koshimizu TA; Nakamura K; Egashira N; Hiroyama M; Nonoguchi H; Tanoue A
    Physiol Rev; 2012 Oct; 92(4):1813-64. PubMed ID: 23073632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.